ArticleFrontiers in oncology2025
CT-based radiomics for prediction of response to neoadjuvant immunochemotherapy in patients with esophageal carcinoma.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In order to investigate the value of radiomic features derived from enhanced computed tomography (CT) for assessment of therapeutic efficacy in patients with Esophageal squamous cell carcinoma (ESCC) underwent neoadjuvant immunochemotherapy (NICT). Methods: The primary cohort of this study included 120 ESCC patients who received NICT from April 2020 to August 2023, comprising 52 patients with good responders (GR) and 68 patients with non-good responders (non-GR) after NICT, the external validation cohort included 30 patients from another hospital, comprising 14 patients with GR and 16 patients with non-GR after NICT. Features were derived from both the intra-tumoral and peri-tumoral regions of the tumor in the enhanced CT image, and the least absolute shrinkage and selection operator (LASSO) regression was used to establish predictive radiomic models (Rad-Scores) and T-stage model for predicting therapeutic response to NICT. Results: The Rad-Score for predicting response to NICT generated the area under the curve (AUC) values of 0.838, 0.831, and 0.769 in the training, internal validation, and external validation cohorts, respectively. For T-stage, corresponding AUC values were 0.809, 0.800, and 0.716 in the same cohorts. Additionally, the nomogram model produced AUC values of 0.867, 0.871, and 0.818 in the training, internal validation, and external validation cohorts, respectively. Conclusions: The established models demonstrate promising predictive potential for assessing the efficacy of NICT in ESCC patients, which may assist clinicians in formulating appropriate treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.